Home › Companies › Acadia Pharmaceuticals Inc. › 2025-2026

Acadia Pharmaceuticals Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Acadia Pharmaceuticals Inc.’s Form 8-K, filed 2026-05-29 (Item 5.07 on EDGAR). Page generated 02 October 2026.

11Reported items
378Asset managers
2,527Fund votes
2026-05-29Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Acadia Pharmaceuticals Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Acadia Pharmaceuticals Inc.

These tallies are Acadia Pharmaceuticals Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Acadia Pharmaceuticals Inc. — official shareholder meeting results, meeting held 2026-05-29
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: James M. Daly	146,927,745	--	--	3,521,002	10,356,394	Majority: yes
Elect Director: Edmund P. Harrigan, M.D.	128,460,130	--	--	21,988,617	10,356,394	Majority: yes
Elect Director: Adora Ndu, Pharm.D., J.D.	134,540,552	--	--	15,908,195	10,356,394	Majority: yes
In addition to the election of three Class I directors, the following matters were submitted to a vote of the stockholders at the Annual Meeting:	148,265,173	1,911,358	272,216	--	10,356,394	Majority: yes

Source: Acadia Pharmaceuticals Inc., Form 8-K, filed with the SEC on 2026-05-29 — read the filing on EDGAR.

How asset managers voted at the Acadia Pharmaceuticals Inc. 2025-2026 meeting

Each item below shows how the 378 asset managers that disclosed a Acadia Pharmaceuticals Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Acadia Pharmaceuticals Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 8 wordings of this item as funds reported it.

99.2% fund support · no official result

FOR 99.1%

The 360 asset managers below cast 99.2% of the shares they voted on this item FOR (151,421,758 for, 1,090,831 against).

FOR: 151,421,758 (99.2%)AGAINST: 1,090,831 (0.7%)ABSTAIN: 196,376 (0.1%)NOT VOTED: 1,000 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BAKER BROS. ADVISORS LP	43,102,442	0	0	For
BlackRock	19,792,852	2,134	0	For
Vanguard	15,814,792	7	1	For
State Street	8,108,101	4,276	0	For
RTW INVESTMENTS, LP	7,144,524	0	0	For
Fidelity	3,794,893	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,466,247	0	0	For
First Trust	3,195,182	0	0	For
Palo Alto Investors LP	2,864,096	0	0	For
Charles Schwab	2,247,763	0	0	For
Point72	1,975,507	0	0	For
PICTET ASSET MANAGEMENT SA	1,839,632	0	0	For
Frazier Life Sciences Management, L.P.	1,438,198	0	0	For
Dimensional	1,418,337	0	0	For
T. Rowe Price	1,253,803	0	0	For
Northern Trust	1,185,566	0	0	For
Nuveen	1,163,143	0	0	For
Artisan	1,156,870	0	0	For
Logos Global Management LP	1,147,084	0	0	For
TIAA	1,141,112	0	0	For
Allspring	1,118,770	0	0	For
John Hancock	1,105,495	0	0	For
Voya	1,066,443	0	0	For
WEATHERBIE CAPITAL, LLC	1,005,974	0	0	For
BRAIDWELL LP	935,406	0	0	For

Showing the 25 largest of 360 asset managers. See all 360 in the interactive database.

2. To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Adora Ndu, Pharm.D., J.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 134,540,552WITHHELD: 15,908,195

Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Adora Ndu, Pharm.D., J.D.”): 134,540,552 for, 15,908,195 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 171,086,205 outstanding shares: 79% for, 9% withheld (88% of the company cast a for/withheld vote).

The 93 asset managers below cast 100% of the shares they voted on this item FOR (46,460,089 for, 0 against).

FOR 87%13%

FOR: 46,460,089 (87.0%)ABSTAIN: 6,831,729 (12.8%)NOT VOTED: 88,571 (0.2%)

Largest asset managers voting on “To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meetin” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	14,866,415	0	For
Vanguard	14,719,012	19,659	For
State Street	19,688	5,634,644	Abstain
Fidelity	3,475,543	0	For
First Trust	3,177,047	0	For
TIAA	1,141,112	0	For
Charles Schwab	1,051,680	0	For
Dimensional	1,000,882	0	For
MFS	621,810	0	For
Invesco	609,164	0	For
John Hancock	542,429	0	For
Columbia Threadneedle	537,427	0	For
Voya	445,735	0	For
ALGER FUNDS	426,213	0	For
T. Rowe Price	0	419,234	Abstain
Equitable	178,870	101,000	For
Bridge Builder Trust	279,264	0	For
Jackson National	230,730	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	For
HUSSMAN INVESTMENT TRUST	180,000	0	For
Prudential/PGIM	164,947	0	For
ALPS ETF Trust	162,935	0	For
Principal Exchange-Traded Funds	158,292	0	For
OLD WESTBURY FUNDS INC	149,600	0	For
Erste Asset Management GmbH	133,700	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

3. To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Edmund P. Harrigan, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 128,460,130WITHHELD: 21,988,617

Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Edmund P. Harrigan, M.D.”): 128,460,130 for, 21,988,617 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 171,086,205 outstanding shares: 75% for, 13% withheld (88% of the company cast a for/withheld vote).

The 93 asset managers below cast 100% of the shares they voted on this item FOR (37,485,338 for, 0 against).

FOR 70%ABSTAIN 29%

FOR: 37,485,338 (70.4%)ABSTAIN: 15,646,480 (29.4%)NOT VOTED: 88,571 (0.2%)

Largest asset managers voting on “To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meetin” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	514,584	14,351,831	Abstain
Vanguard	14,702,586	36,085	For
State Street	5,646,482	7,850	For
Fidelity	3,421,607	53,936	For
First Trust	3,177,047	0	For
TIAA	1,141,112	0	For
Charles Schwab	1,051,680	0	For
Dimensional	1,000,882	0	For
MFS	621,810	0	For
Invesco	609,164	0	For
John Hancock	542,429	0	For
Columbia Threadneedle	537,427	0	For
Voya	445,735	0	For
ALGER FUNDS	426,213	0	For
T. Rowe Price	0	419,234	Abstain
Equitable	0	279,870	Abstain
Bridge Builder Trust	255,128	24,136	For
Jackson National	230,730	0	For
QUANTITATIVE MASTER SERIES LLC	0	203,782	Abstain
Prudential/PGIM	164,947	0	For
ALPS ETF Trust	162,935	0	For
Principal Exchange-Traded Funds	158,292	0	For
OLD WESTBURY FUNDS INC	149,600	0	For
Erste Asset Management GmbH	133,700	0	For
Lincoln Financial	130,710	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

4. To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: James M. Daly

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 146,927,745WITHHELD: 3,521,002

Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: James M. Daly”): 146,927,745 for, 3,521,002 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 171,086,205 outstanding shares: 86% for, 2% withheld (88% of the company cast a for/withheld vote).

The 93 asset managers below cast 100% of the shares they voted on this item FOR (52,409,427 for, 0 against).

FOR 98%

FOR: 52,409,427 (98.5%)ABSTAIN: 722,391 (1.4%)NOT VOTED: 88,571 (0.2%)

Largest asset managers voting on “To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meetin” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	14,866,415	0	For
Vanguard	14,702,670	36,001	For
State Street	5,646,482	7,850	For
Fidelity	3,475,543	0	For
First Trust	3,177,047	0	For
TIAA	1,141,112	0	For
Charles Schwab	1,051,680	0	For
Dimensional	1,000,882	0	For
MFS	621,810	0	For
Invesco	609,164	0	For
John Hancock	542,429	0	For
Columbia Threadneedle	537,427	0	For
Voya	445,735	0	For
ALGER FUNDS	426,213	0	For
T. Rowe Price	0	419,234	Abstain
Equitable	178,870	101,000	For
Bridge Builder Trust	279,264	0	For
Jackson National	230,730	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	For
Prudential/PGIM	164,947	0	For
ALPS ETF Trust	162,935	0	For
Principal Exchange-Traded Funds	158,292	0	For
OLD WESTBURY FUNDS INC	149,600	0	For
Erste Asset Management GmbH	133,700	0	For
Lincoln Financial	130,710	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

5. TO APPROVE AN AMENDMENT TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 5,209,670 SHARES.

COMPENSATION

99.2% fund support · no official result

FOR 99.2%

The 92 asset managers below cast 99.2% of the shares they voted on this item FOR (52,713,939 for, 405,344 against).

FOR: 52,713,939 (99.2%)AGAINST: 405,344 (0.8%)ABSTAIN: 16,375 (0.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGRE” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,866,415	0	For
Vanguard	14,702,637	36,034	For
State Street	5,646,194	8,138	For
Fidelity	3,475,543	0	For
First Trust	3,177,047	0	For
TIAA	1,141,112	0	For
Charles Schwab	1,051,680	0	For
Dimensional	1,000,882	0	For
MFS	621,810	0	For
Invesco	609,164	0	For
John Hancock	542,429	0	For
Columbia Threadneedle	537,427	0	For
Voya	445,735	0	For
ALGER FUNDS	426,213	0	For
T. Rowe Price	419,234	0	For
Equitable	279,870	0	For
Bridge Builder Trust	279,264	0	For
Jackson National	230,730	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	For
HUSSMAN INVESTMENT TRUST	0	180,000	Against
Prudential/PGIM	164,947	0	For
ALPS ETF Trust	162,935	0	For
Principal Exchange-Traded Funds	158,292	0	For
OLD WESTBURY FUNDS INC	149,600	0	For
Lincoln Financial	130,710	0	For

Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.

6. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

99.0% fund support · no official result

FOR 99.0%

The 90 asset managers below cast 99.0% of the shares they voted on this item FOR (52,618,839 for, 496,232 against).

FOR: 52,618,839 (99.0%)AGAINST: 496,232 (0.9%)ABSTAIN: 16,375 (0.0%)

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,866,415	0	For
Vanguard	14,738,657	14	For
State Street	5,651,683	2,649	For
Fidelity	3,475,543	0	For
First Trust	3,177,047	0	For
TIAA	1,141,112	0	For
Charles Schwab	1,051,680	0	For
Dimensional	1,000,882	0	For
MFS	621,810	0	For
Invesco	609,164	0	For
John Hancock	542,429	0	For
Columbia Threadneedle	537,427	0	For
Voya	445,735	0	For
ALGER FUNDS	0	426,213	Against
T. Rowe Price	419,234	0	For
Equitable	279,870	0	For
Bridge Builder Trust	279,264	0	For
Jackson National	230,730	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	For
HUSSMAN INVESTMENT TRUST	180,000	0	For
Prudential/PGIM	164,947	0	For
ALPS ETF Trust	162,935	0	For
Principal Exchange-Traded Funds	158,292	0	For
OLD WESTBURY FUNDS INC	149,600	0	For
Lincoln Financial	130,710	0	For

Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

46.4% fund support · no official result

FOR 38%AGAINST 44%NOT VOTED 17%

The 8 asset managers below cast 46.4% of the shares they voted on this item FOR (197,793 for, 228,125 against).

FOR: 197,793 (38.4%)AGAINST: 228,125 (44.3%)NOT VOTED: 88,571 (17.2%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Vote
NORDEA INVESTMENT MANAGEMENT AB	0	228,125	Against
Erste Asset Management GmbH	133,700	0	For
Empower	0	0	Not Voted
CLEARWATER INVESTMENT TRUST	26,672	0	For
Wilshire Advisors LLC	24,199	0	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	12,839	0	For
Cornerstone Investment Partners, LLC	383	0	For
Torrey Growth & Income Advisors	0	0	--

8. Amend Omnibus Stock Plan

COMPENSATION

100% fund support · no official result

FOR 64%NOT VOTED 36%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (160,372 for, 0 against).

FOR: 160,372 (64.4%)NOT VOTED: 88,571 (35.6%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Vote
Erste Asset Management GmbH	133,700	For
Empower	0	Not Voted
CLEARWATER INVESTMENT TRUST	26,672	For

9. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 64%NOT VOTED 36%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (160,372 for, 0 against).

FOR: 160,372 (64.4%)NOT VOTED: 88,571 (35.6%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Vote
Erste Asset Management GmbH	133,700	For
Empower	0	Not Voted
CLEARWATER INVESTMENT TRUST	26,672	For

10. SAY ON PAY

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (165 for, 0 against).

FOR: 165 (100.0%)

Largest asset managers voting on “SAY ON PAY” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Vote
Empower	165	For
Ikarian Capital, LLC	0	--
Verdad Advisers, LP	0	--

11. To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (212 for, 0 against).

FOR: 212 (100.0%)

Largest asset managers voting on “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Modern Wealth Management, LLC	106	0	0	0	For
Tandem Financial, LLC	106	0	0	0	For

Largest Acadia Pharmaceuticals Inc. shareholders voting in 2025-2026

Ranked by the number of Acadia Pharmaceuticals Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 171,086,205 shares outstanding at the time of that meeting.

Top Acadia Pharmaceuticals Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	BAKER BROS. ADVISORS LP	25.19%
2	BlackRock	11.57%
3	Vanguard	9.24%
4	State Street	4.74%
5	RTW INVESTMENTS, LP	4.18%
6	Fidelity	2.22%
7	GEODE CAPITAL MANAGEMENT, LLC	2.03%
8	First Trust	1.87%
9	Palo Alto Investors LP	1.67%
10	Charles Schwab	1.31%

Reported Acadia Pharmaceuticals Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Acadia Pharmaceuticals Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Baker Bros. Advisors LP	25.34%	DEF14A
Julian C. Baker	25.34%	DEF14A
Stephen R. Biggar	25.28%	DEF14A
BlackRock	12.60%	13F
Vanguard Group	8.86%	13F
State Street	4.87%	13F
Geode Capital	2.03%	13F
Dimensional Fund Advisors	1.84%	13F
Point72	1.52%	13F
Renaissance Technologies	1.01%	13F

Percentages above are of 171,086,205 shares outstanding, as reported by Acadia Pharmaceuticals Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Acadia Pharmaceuticals Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Acadia Pharmaceuticals Inc.'s shareholder meeting held 2026-05-29, in the 2025-2026 proxy season, 378 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,527 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Acadia Pharmaceuticals Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory basis, the compensation of the Company's named executive officers… — the reporting funds cast 99.2% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Acadia Pharmaceuticals Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).